A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY4064809 Combined with a CDK4/6 Inhibitor and Endocrine Therapy in Adults with HR+, HER2- Advanced Breast Cancer with a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)

17049J6M-MC-JSGD-NCT07174336OpenA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY4064809 Combined with a CDK4/6 Inhibitor and Endocrine Therapy in Adults with HR+, HER2- Advanced Breast Cancer with a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2) J6M-MC-JSGDNCT07174336IndustrialAdultTreatmentIIIGlobalBreastChitalia, AmiMedStar Health and GUMC; Medstar Washington Hospital CenterBreastOncology GroupMHRI Washington Cancer Institute2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>